Organogenesis (NASDAQ:ORGO) reported a sharp year-over-year revenue decline in the first quarter of 2026, with executives ...

Detailed price information for Organogenesis Holdings Inc (ORGO-Q) from The Globe and Mail including charting and trades.

CFO Francisco noted, "Our 2026 total revenue guidance now reflects the expectation that we see more measured improvement in clinician confusion and the overall operating environment as we move through ...

Guidance language tightened: Q4 2025 guided to "total net revenue" decline of "25% to 38%" (Chief Financial Officer Francisco, Q4 2025), while Q1 2026 updated to "$270 million to $310 million" and "a ...

Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of ...

Welcome, ladies and gentlemen, to the First Quarter 2026 Earnings Conference Call for Organogenesis Holdings, Inc. [Operator Instructions] Please note that this conference call is being recorded, and ...

The updated 2026 revenue guidance assumes a more measured and prolonged recovery, with market-related headwinds expected to ...

Animal embryogenesis is the process by which the embryo develops from the fertilised egg cell. Important events that occur during embryogenesis are gastrulation, formation of the early nervous system ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...